KPB82 potently and selectively inhibits ACER2 and protects tumor and primary cells from doxorubicin-induced cytotoxicity
Alkaline ceramidase 2 (ACER2) catalyzes the hydrolysis of ceramides into sphingosine and free fatty acids, playing crucial roles in regulating various biological processes, including but not limited to cell proliferation, survival, and the DNA damage response. However, a pharmacological tool that regulates its catalytic and signaling functions remains to be developed. In this study,…
KPB82 is a novel compound that effectively inhibits alkaline ceramidase 2 (ACER2) while displaying limited activity on other ceramidases. In vitro enzymatic tests demonstrated that KPB82 has an IC50 of just 190 nM for inhibiting ACER2, compared to over 100 microM for neutral ceramidases and negligible inhibition of ACER1 or ACER3.
Molecular modeling and docking studies showed that KPB82 binds to ACER2 within a specific pocket, forming crucial hydrogen bonds with key residues Asp93 and His215 and interacting with hydrophobic residues. This potent inhibition of ACER2 was demonstrated to reduce lactate dehydrogenase release - a marker of cell toxicity - in ACER2-overexpressing cancer cell lines exposed to the chemotherapy drug doxorubicin.
By blocking ACER2 function, KPB82 potentially suppresses the production of sphingosine and other ceramide-derived mediators. These findings establish KPB82 as a highly selective inhibitor of ACER2, opening avenues for studying the critical role of ceramide metabolism and ACER2 signaling in cancer cell survival and response to chemotherapy.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.